SCHEMBL2651772

SCHEMBL2651772

COc1ccnc(-c2cc(N)ccc2F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.56
CCR5 P51681 1/20 0.56
CCR8 P51685 1/20 0.56
NOS3 P29474 2/20 0.49
NOS1 P29475 2/20 0.49
NOS2 P35228 2/20 0.49
KDM1A O60341 1/20 0.46
KDM4C Q9H3R0 2/20 0.46
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
PLAU P00749 1/20 0.42
TGFBR1 P36897 6/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP3A4 P08684 1/20 0.40
MAP4K4 O95819 1/20 0.37
CCR9 P51686 1/20 0.37
KIT P10721 1/20 0.36
DYRK1A Q13627 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27322683 0.87 CCR1 (0.63) CCR1CCR5CCR8NOS3NOS1
SCHEMBL27592804 0.84 CCR1 (0.59) CCR1CCR5CCR8NOS3NOS1
SCHEMBL7239732 0.83 CCR1 (0.58) CCR1CCR5CCR8NOS3NOS1
SCHEMBL13985936 0.82 CCR1 (0.66) CCR1CCR5CCR8NOS3NOS1
SCHEMBL2653354 0.82 CCR1 (0.56) CCR1CCR5CCR8NOS3NOS1
SCHEMBL2652006 0.80 CCR1 (0.52) CCR1CCR5CCR8NOS3NOS1
SCHEMBL2653522 0.76 CCR1 (0.49) CCR1CCR5CCR8NPC1RAB9A
SCHEMBL7231676 0.76 CCR1 (0.56) CCR1CCR5CCR8NOS3NOS1
SCHEMBL7230635 0.76 CCR1 (0.56) CCR1CCR5CCR8NOS3NOS1
SCHEMBL12828417 0.76 CCR1 (0.56) CCR1CCR5CCR8NOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1381606-B1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2005-07-20 EP disclosed
US-6900215-B2 For therapy of disorders of central nervous system, including anxiety, convulsions and cognitive disorders MERCK SHARP & DOHME LTD. (GB) 2005-05-31 US disclosed
EP-1381606-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2004-01-21 EP disclosed
US-20020193385-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors MERCK SHARP & DOHME (UK) LIMITED (GB) 2002-12-19 US disclosed
WO-2002074773-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193385-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors GABRA3, GABRA1, GABRA2 CCR1 1269/4885CCR5 1647/4885CCR8 1814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.